UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Biomarkers in atopic dermatitis—a review on behalf of the International Eczema Council

Journal of allergy and clinical immunology, 2021-04, Vol.147 (4), p.1174-1190.e1

2021

Volltextzugriff (PDF)

SARS-CoV-2 Transmission from Presymptomatic Meeting Attendee, Germany

Emerging infectious diseases, 2020-08, Vol.26 (8), p.1935-1937

2020

Volltextzugriff (PDF)

Moving toward endotypes in atopic dermatitis: Identification of patient clusters based on serum biomarker analysis

Journal of allergy and clinical immunology, 2017-09, Vol.140 (3), p.730-737

2017

Volltextzugriff (PDF)

Needs and preferences of patients regarding atopic dermatitis care in the era of new therapeutic options: a qualitative study

Archives of Dermatological Research, 2023-01, Vol.315 (1), p.75-83

2023

Volltextzugriff (PDF)

Multiplex platform technology and bioinformatics are essential for development of biomarkers in atopic dermatitis

Journal of allergy and clinical immunology, 2017-03, Vol.139 (3), p.1065-1065

2017

Volltextzugriff (PDF)

Current and Future Biomarkers in Atopic Dermatitis

Immunology and allergy clinics of North America, 2017-02, Vol.37 (1), p.51-61

2017

Volltextzugriff (PDF)

Utility of serum thymus and activation-regulated chemokine as a biomarker for monitoring of atopic dermatitis severity

Journal of the American Academy of Dermatology, 2014-12, Vol.71 (6), p.1160-1166

2014

Volltextzugriff (PDF)

Epicutaneous application of house dust mite induces thymic stromal lymphopoietin in nonlesional skin of patients with atopic dermatitis

Journal of allergy and clinical immunology, 2013-11, Vol.132 (5), p.1252-1254

2013

Volltextzugriff (PDF)

Higher prevalence of dupilumab‐induced ocular adverse events in atopic dermatitis compared to asthma: A daily practice analysis

Clinical and translational allergy, 2024-08, Vol.14 (8), p.e12386-n/a

2024

Volltextzugriff (PDF)

Prediction of response to dupilumab treatment

British journal of dermatology (1951), 2023-05, Vol.188 (6), p.e41-e41

2023

Volltextzugriff (PDF)

Cyclosporin A reduces CD4+ CD25+ regulatory T-cell numbers in patients with atopic dermatitis

Journal of allergy and clinical immunology, 2009-10, Vol.124 (4), p.856-858

2009

Volltextzugriff (PDF)

Brief Report: Enrichment of Activated Group 3 Innate Lymphoid Cells in Psoriatic Arthritis Synovial Fluid

Arthritis & rheumatology (Hoboken, N.J.), 2015-10, Vol.67 (10), p.2673-2678

2015

Volltextzugriff (PDF)

New Developments in Biomarkers for Atopic Dermatitis

Journal of clinical medicine, 2015-03, Vol.4 (3), p.479-487

2015

Volltextzugriff (PDF)

Biomarkers for atopic dermatitis: a systematic review and meta-analysis

Current opinion in allergy and clinical immunology, 2015-10, Vol.15 (5), p.453-460

2015

Volltextzugriff (PDF)

Long-term effectiveness and safety of treatment with dupilumab in patients with atopic dermatitis: Results of the TREAT NL (TREatment of ATopic eczema, the Netherlands) registry

Journal of the American Academy of Dermatology, 2020-11, Vol.83 (5), p.1375-1384

2020

Volltextzugriff (PDF)

PD-1+CD8+ T cells are clonally expanding effectors in human chronic inflammation

The Journal of clinical investigation, 2018-10, Vol.128 (10), p.4669-4681

2018

Volltextzugriff (PDF)

CD8+ T Cells in the Lesional Skin of Atopic Dermatitis and Psoriasis Patients Are an Important Source of IFN-γ, IL-13, IL-17, and IL-22

Journal of investigative dermatology, 2013-04, Vol.133 (4), p.973-979

2013

Volltextzugriff (PDF)

European Task Force on Atopic Dermatitis statement on severe acute respiratory syndrome coronavirus 2 (SARS‐Cov‐2) infection and atopic dermatitis

Journal of the European Academy of Dermatology and Venereology, 2020-06, Vol.34 (6), p.e241-e242

2020

Volltextzugriff (PDF)

Upadacitinib treatment in a real‐world difficult‐to‐treat atopic dermatitis patient cohort

Journal of the European Academy of Dermatology and Venereology, 2024-02, Vol.38 (2), p.384-392

2024

Volltextzugriff (PDF)

Serum biomarker profiles suggest that atopic dermatitis is a systemic disease

Journal of allergy and clinical immunology, 2018-04, Vol.141 (4), p.1523-1526

2018

Volltextzugriff (PDF)

Immunohistochemical Characterization of the IL-13:IL-4 Receptor α Axis in the Skin of Adult Patients with Moderate to Severe Atopic Dermatitis and Healthy Controls

Journal of investigative dermatology, 2021-02, Vol.141 (2), p.440-443.e4

2021

Volltextzugriff (PDF)

EASI p‐EASI: Predicting disease severity in atopic dermatitis patients treated with dupilumab using a combination of serum biomarkers

Allergy (Copenhagen), 2020-12, Vol.75 (12), p.3287-3289

2020

Volltextzugriff (PDF)

Genetic Susceptibility to Dry Skin in a General Middle-Aged to Elderly Population: A GWAS

Journal of investigative dermatology, 2021-08, Vol.141 (8), p.2077-2079.e5

2021

Volltextzugriff (PDF)

Atopic dermatitis: A tale of two distinct pathomechanisms that make you itch

European journal of immunology, 2016-11, Vol.46 (11), p.2512-2515

2016

Volltextzugriff (PDF)

Response to: “Comment on ‘Long-term effectiveness and safety of treatment with dupilumab in patients with atopic dermatitis: Results of the TREAT NL (TREatment of ATopic eczema, the Netherlands) registry’”

Journal of the American Academy of Dermatology, 2021-09, Vol.85 (3), p.e173-e174

2021

Volltextzugriff (PDF)

1 – 25 von 56

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(54)
Mit Volltextzugriff
(51)

Publikationsform

Artikel
(56)

Sprache

Englisch
(56)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Biomarkers in atopic dermatitis—a review on behalf of the International Eczema Council

SARS-CoV-2 Transmission from Presymptomatic Meeting Attendee, Germany

Moving toward endotypes in atopic dermatitis: Identification of patient clusters based on serum biomarker analysis

Needs and preferences of patients regarding atopic dermatitis care in the era of new therapeutic options: a qualitative study

Multiplex platform technology and bioinformatics are essential for development of biomarkers in atopic dermatitis

Current and Future Biomarkers in Atopic Dermatitis

Utility of serum thymus and activation-regulated chemokine as a biomarker for monitoring of atopic dermatitis severity

Epicutaneous application of house dust mite induces thymic stromal lymphopoietin in nonlesional skin of patients with atopic dermatitis

Higher prevalence of dupilumab‐induced ocular adverse events in atopic dermatitis compared to asthma: A daily practice analysis

Prediction of response to dupilumab treatment

Cyclosporin A reduces CD4+ CD25+ regulatory T-cell numbers in patients with atopic dermatitis

Brief Report: Enrichment of Activated Group 3 Innate Lymphoid Cells in Psoriatic Arthritis Synovial Fluid

New Developments in Biomarkers for Atopic Dermatitis

Biomarkers for atopic dermatitis: a systematic review and meta-analysis

Long-term effectiveness and safety of treatment with dupilumab in patients with atopic dermatitis: Results of the TREAT NL (TREatment of ATopic eczema, the Netherlands) registry

PD-1+CD8+ T cells are clonally expanding effectors in human chronic inflammation

CD8+ T Cells in the Lesional Skin of Atopic Dermatitis and Psoriasis Patients Are an Important Source of IFN-γ, IL-13, IL-17, and IL-22

European Task Force on Atopic Dermatitis statement on severe acute respiratory syndrome coronavirus 2 (SARS‐Cov‐2) infection and atopic dermatitis

Upadacitinib treatment in a real‐world difficult‐to‐treat atopic dermatitis patient cohort

Serum biomarker profiles suggest that atopic dermatitis is a systemic disease

Immunohistochemical Characterization of the IL-13:IL-4 Receptor α Axis in the Skin of Adult Patients with Moderate to Severe Atopic Dermatitis and Healthy Controls

EASI p‐EASI: Predicting disease severity in atopic dermatitis patients treated with dupilumab using a combination of serum biomarkers

Genetic Susceptibility to Dry Skin in a General Middle-Aged to Elderly Population: A GWAS

Atopic dermatitis: A tale of two distinct pathomechanisms that make you itch

Response to: “Comment on ‘Long-term effectiveness and safety of treatment with dupilumab in patients with atopic dermatitis: Results of the TREAT NL (TREatment of ATopic eczema, the Netherlands) registry’”

Suchergebnisse filtern